CyclosporineCyclic peptide medicine
Cyclosporine, also spelled ciclosporin, suppresses selected immune signalling. Its clinical role and risks depend heavily on whether exposure is systemic or local, such as an eye-drop formulation.
What is Cyclosporine?
Cyclosporine is a cyclic peptide immunosuppressant used in transplantation and selected inflammatory conditions. Systemic and ophthalmic formulations have different clinical contexts.
How it works
It inhibits calcineurin-mediated signalling and reduces T-cell activation. The intended effect is suppression of particular immune activity, not general immune enhancement.
Effects studied
Transplantation and inflammatory disease
Systemic treatment is assessed through outcomes such as rejection prevention and organ function; ophthalmic treatment through eye-specific symptoms and findings. 1
Evidence: Evidence must remain tied to the indication and formulation.
What does the evidence show?
Established indication-specific medicine; retained clinical reference
A peptide that restrains immune activation
Cyclosporine is a cyclic peptide that inhibits calcineurin-mediated signalling, affecting activation of T cells. This helps explain its use where immune activity threatens transplanted tissue or contributes to inflammatory disease. It is not a general immune “booster”; the intended effect goes in a different direction.
Systemic and local treatment differ
An oral or injected formulation exposes the body differently from treatment applied to the eye. The benefits and adverse effects therefore need to be discussed for the actual product. Evidence from transplantation cannot simply be used to describe the experience of someone using an ophthalmic preparation.
Why monitoring is part of treatment
Systemic use can affect kidney function and blood pressure, and interactions can change exposure substantially. Infection and malignancy risks are relevant to immunosuppression. These risks need to be weighed against the expected benefit of treatment.
What counts as successful treatment
In transplantation, preserving organ function and preventing rejection are meaningful outcomes. In an inflammatory eye condition, symptoms and surface findings may matter instead. The same receptor pathway does not create one universal outcome or safety profile. Understanding cyclosporine requires knowing the condition being treated, the formulation used and the monitoring it needs.
Safety & status
Systemic exposure can affect kidney function and blood pressure. Interactions can substantially alter exposure; infection and malignancy risks are relevant to immunosuppression. These risks should not be transferred unchanged to local eye treatment.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is cyclosporine an immune booster?
No. Its therapeutic mechanism suppresses aspects of immune activation.
Do oral and eye preparations have the same risk profile?
No. Their exposure and treatment purposes differ, so each requires product-specific assessment.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Cyclosporine · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.